中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

85 records (took 0.022 seconds)

    DEVELOPMENT OF THE SOLUBLE RECOMBINANT CRM197 PRODUCTION BY E. COLI
    52.
    发明申请
    DEVELOPMENT OF THE SOLUBLE RECOMBINANT CRM197 PRODUCTION BY E. COLI 审中-公开
    可溶性重组CRM197生产的发展

    公开(公告)号：US20150184215A1

    公开(公告)日：2015-07-02

    申请号：US14584836

    申请日：2014-12-29

    Applicant: Development Center for Biotechnology

    Inventor： Yu-Shen Hsu ,  Show-Shan Sheu ,  Bo-Chin Lei ,  Tsan-Hui Wu

    IPC: C12P21/00 ,  C07K1/20 ,  C07K14/34 ,  C07K1/18 ,  C07K1/22

    CPC classification number: C07K1/20 ,  C07K14/34 ,  C12P21/02

    Abstract: A method for recombinant production of a CRM197 protein includes culturing a recombinant Escherichia coli cell to produce said CRM197 protein, and isolating said CRM197 protein. The recombinant Escherichia coli cell includes an expression vector, which contains a nucleic acid molecule that encodes a fusion protein that includes an E. coli periplasmic signal peptide at N terminal and the CRM197 at C terminal. The CRM197 is encoded by a polynucleotide having the sequence of SEQ ID NO: 1. The E. coli periplasmic signal peptide comprise a pelB leader sequence. The nucleic acid molecule comprises the sequence of SEQ ID NO:2. The Escherichia coli cell is BL21(DE3)pLysS.

    Abstract translation: 重组生产CRM197蛋白的方法包括培养重组大肠杆菌细胞以产生所述CRM197蛋白，并分离所述CRM197蛋白。 重组大肠杆菌细胞包含表达载体，其含有编码融合蛋白的核酸分子，所述融合蛋白包括N末端的大肠杆菌周质信号肽和C末端的CRM197。 CRM197由具有SEQ ID NO：1的序列的多核苷酸编码。大肠杆菌周质信号肽包含pelB前导序列。 核酸分子包含SEQ ID NO：2的序列。 大肠杆菌细胞是BL21（DE3）pLysS。

    PLANT EXTRACT AND THE PROCESS FOR TREATING HEPATIC FIBROSIS AND LIVER CANCER
    53.
    发明申请
    PLANT EXTRACT AND THE PROCESS FOR TREATING HEPATIC FIBROSIS AND LIVER CANCER 有权
    植物提取物和治疗肝硬化和肝癌的方法

    公开(公告)号：US20150182572A1

    公开(公告)日：2015-07-02

    申请号：US14144264

    申请日：2013-12-30

    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

    Inventor： Yuh-Shan Chung ,  Ma-Li Siu ,  Tzung-Hsien Lai ,  Szu-Chien Yeh

    IPC: A61K36/41

    CPC classification number: A61K36/41 ,  A61K2236/00

    Abstract: An extract of Graptopetalum paraguayense prepared by a method that includes: extracting a Graptopetalum paraguayense (GP) starting material with an alcoholic solvent to produce an alcoholic extract and a residue; separating the residue from the alcoholic extract; extracting the residue with an aqueous dimethyl sulfoxide (DMSO) solvent to produce a DMSO extract; subjecting the DMSO extract to ultrafiltration using a filter having a selected molecular weight cutoff; drying a fraction retained by the filter to obtain the extract of Graptopetalum paraguayense. Uses of an extract of Graptopetalum paraguayense for the treatment or prevention of liver fibrosis, hepatic cirrhosis, liver cancer, recurrence of liver fibrosis after surgery, or recurrence of liver cancer after surgery.

    Abstract translation: 通过包括以下方法制备的Graptopetalum巴拉圭的提取物包括：用醇溶剂萃取Graptopetalum巴拉圭（GP）起始原料以产生醇提取物和残余物; 从酒精提取物中分离残留物; 用二甲基亚砜（DMSO）水溶液萃取残余物，得到DMSO提取物; 使用具有选择的分子量截止值的过滤器对DMSO提取物进行超滤; 干燥由过滤器保留的部分，以获得格拉菲叶醋巴拉圭的提取物。 Graptopetalum paraguayense的提取物用于治疗或预防肝纤维化，肝硬化，肝癌，手术后肝纤维化复发或手术后肝癌复发。

    ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHOD OF USE IN IMMUNE DISEASES
    54.
    发明申请
    ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHOD OF USE IN IMMUNE DISEASES 有权
    ALPHA-ENOLASE特异性抗体及其在免疫疾病中的使用方法

    公开(公告)号：US20150175710A1

    公开(公告)日：2015-06-25

    申请号：US14580127

    申请日：2014-12-22

    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

    Inventor： Shih-Chong Tsai ,  Mingl Chang ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Shyi-Jou Chen ,  Wei-Tso Chia ,  Hsin-Yun Wang

    IPC: C07K16/40 ,  A61K39/39 ,  A61K39/395

    CPC classification number: A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  B63B1/121 ,  B63B15/02 ,  B63B2001/123 ,  B63B2015/005 ,  B63H9/08 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

    Abstract: A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)2 fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.

    Abstract translation: 用于治疗炎性疾病或免疫疾病的方法包括向需要这种治疗的受试者施用针对ENO1的拮抗剂。 拮抗剂结合ENO1并抑制ENO1纤溶酶原受体活性。 拮抗剂可以是特异性结合人ENO1（GenBank：AAH50642.1）用于治疗炎性疾病或免疫疾病的抗人ENO1抗体或其scFv，Fab或F（ab）2片段） ，可能是多发性硬化症，类风湿性关节炎，克罗恩病，溃疡性结肠炎，系统性红斑狼疮，慢性阻塞性肺病（COPD），哮喘，过敏，牛皮癣，1型糖尿病，动脉粥样硬化或骨质疏松症。

Patent Agency Ranking